Lim, Songhyun Lee, Sanghee 2024-01-19T11:31:28Z 2024-01-19T11:31:28Z 2022-09-08 2022-08 1420-3049 https://pubs.kist.re.kr/handle/201004/114791 Autism spectrum disorders (ASD) are neurodevelopmental disorders characterized by diverse behavioral symptoms such as repetitive behaviors, social deficits, anxiety, hyperactivity, and irritability. Despite their increasing incidence, the specific pathological mechanisms of ASD are still unknown, and the degree and types of symptoms that vary from patient to patient make it difficult to develop drugs that target the core symptoms of ASD. Although various atypical antipsychotics and antidepressants have been applied to regulate ASD symptoms, these drugs can only alleviate the symptoms and do not target the major causes. Therefore, development of novel drugs targeting factors directly related to the onset of ASD is required. Among the various factors related to the onset of ASD, several chemical modulators to treat ASD, focused on serotonin (5-hydroxytryptamine, 5-HT) and glutamate receptors, microbial metabolites, and inflammatory cytokines, are explored in this study. In particular, we focus on the chemical drugs that have improved various aspects of ASD symptoms in animal models and in clinical trials for various ages of patients with ASD. English Multidisciplinary Digital Publishing Institute (MDPI) Chemical Modulators for Targeting Autism Spectrum Disorders: From Bench to Clinic Article 10.3390/molecules27165088 1 Molecules, v.27, no.16 Molecules 27 16 Y scie scopus 000845338100001 Biochemistry & Molecular Biology Chemistry, Multidisciplinary Biochemistry & Molecular Biology Chemistry Review BTBR MOUSE MODEL PERVASIVE DEVELOPMENTAL DISORDERS METABOTROPIC GLUTAMATE RECEPTORS OPEN-LABEL TRIAL DOUBLE-BLIND RISPERIDONE TREATMENT YOUNG-CHILDREN D-CYCLOSERINE ANIMAL-MODEL SOCIAL DEFICITS autism spectrum disorders 5-hydroxytryptamine glutamate microbial metabolites inflammatory cytokines